Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nisoldipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 10/20 | 1.00 |
| ▸ | CACNA1F known ✓ | O60840 | 9/20 | 1.00 |
| ▸ | CACNA1D known ✓ | Q01668 | 9/20 | 1.00 |
| ▸ | CACNA1S known ✓ | Q13698 | 9/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 2/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | SCN1A | P35498 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 2/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 2/20 | 1.00 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nisoldipine SCHEMBL29420725 | 1.00 | CACNA1C (1.00) | CACNA1CCACNA1FCACNA1DCACNA1SADORA3 | |
| Nisoldipine SCHEMBL19348996 | 1.00 | CACNA1C (1.00) | CACNA1CCACNA1FCACNA1DCACNA1SADORA3 | |
| Nisoldipine SCHEMBL39779 | 1.00 | CACNA1C (1.00) | CACNA1CCACNA1FCACNA1DCACNA1SADORA3 | |
| Nisoldipine SCHEMBL39780 | 1.00 | CACNA1C (1.00) | CACNA1CCACNA1FCACNA1DCACNA1SADORA3 | |
| Nisoldipine SCHEMBL919020 | 0.99 | CACNA1C (0.98) | CACNA1CCACNA1FCACNA1DCACNA1SADORA3 | |
| Nisoldipine SCHEMBL27608147 | 0.99 | CACNA1C (0.98) | CACNA1CCACNA1FCACNA1DCACNA1SADORA3 | |
| Nisoldipine SCHEMBL3855961 | 0.99 | CACNA1C (0.98) | CACNA1CCACNA1FCACNA1DCACNA1SADORA3 | |
| SCHEMBL4608536 | 0.96 | CACNA1D (0.92) | CACNA1CCACNA1FCACNA1DCACNA1SADORA3 | |
| SCHEMBL9765770 | 0.93 | CACNA1C (0.86) | CACNA1CCACNA1FCACNA1DCACNA1SADORA3 | |
| SCHEMBL7432246 | 0.92 | CACNA1C (0.84) | CACNA1CCACNA1FCACNA1DCACNA1SADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230256161-A9 | Methods and Compositions for Treating a Disease Condition in a Subject | Palo Alto Investors LP | 2023-08-17 | — | — | US | disclosed |
| US-11382513-B2 | Methods and compositions for treating a condition in a subject | PALO ALTO INVESTORS (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210121625-A1 | Methods and Compositions for Treating a Disease Condition in a Subject | YUN ANTHONY JOONKYOO (US) | 2021-04-29 | — | — | US | disclosed |
| US-20200360271-A1 | Methods and Compositions for Treating a Renal Disease Condition in a Subject | Palo Alto Investors LP | 2020-11-19 | — | — | US | disclosed |
| US-10716749-B2 | Methods and compositions for treating a renal disease condition in a subject | PALO ALTO INVESTORS (US) | 2020-07-21 | — | — | US | disclosed |
| US-20180125419-A1 | Methods and Compositions for Treating a Condition in a Subject | PALO ALTO INVESTORS | 2018-05-10 | — | — | US | disclosed |
| US-9833618-B2 | Methods and compositions for treating a disease condition in a subject | PALO ALTO INVESTORS (US) | 2017-12-05 | — | — | US | disclosed |
| US-9622980-B2 | Controlled release compositions | JAGOTEC AG (GB) | 2017-04-18 | — | — | US | disclosed |
| US-20160008288-A1 | Controlled Release Compositions | JAGOTEC AG (CH) | 2016-01-14 | — | — | US | disclosed |
| US-9101544-B2 | Controlled release nisoldipine compositions | JAGOTEC AG (CH) | 2015-08-11 | — | — | US | disclosed |
| EP-2063872-A1 | CONTROLLED RELEASE ORAL DOSAGE FORMULATIONS COMPRISING A CORE AND ONE OR MORE BARRIER LAYERS | Jagotec AG (CH) | 2009-06-03 | — | — | EP | disclosed |
| US-20080221174-A1 | CONTROLLED RELEASE NISOLDIPINE COMPOSITIONS | JAGOTEC AG | 2008-09-11 | — | — | US | disclosed |
| US-20080063711-A1 | Controlled Release Nisoldipine Compositions | JAGOTEC AG | 2008-03-13 | — | — | US | disclosed |
| WO-2008025535-A1 | CONTROLLED RELEASE ORAL DOSAGE FORMULATIONS COMPRISING A CORE AND ONE OR MORE BARRIER LAYERS | JAGOTEC AG (CH) | 2008-03-06 | — | — | WO | disclosed |
| US-20080057123-A1 | Controlled Release Formulations | JAGOTEC AG | 2008-03-06 | — | — | US | disclosed |
| WO-2008025532-A1 | CONTROLLED RELEASE SOLID ORAL DOSAGE FORMULATIONS COMPRISING NISOLDIPINE | JAGOTEC AG (CH) | 2008-03-06 | — | — | WO | disclosed |
| US-20070112327-A1 | Methods and compositions for treating a renal disease condition in a subject | PALO ALTO INVESTORS | 2007-05-17 | — | — | US | disclosed |
| US-20060206149-A1 | Methods and compositions for treating a disease condition in a subject | PALO ALTO INVESTORS | 2006-09-14 | — | — | US | disclosed |
| US-20060116721-A1 | Methods and compositions for treating a disease condition in a subject | PALO ALTO INVESTORS | 2006-06-01 | — | — | US | disclosed |
| WO-2006044694-A2 | METHODS AND COMPOSITIONS FOR TREATING A DISEASE CONDITION IN A SUBJECT | PALO ALTO INVESTORS (US) | 2006-04-27 | — | — | WO | disclosed |